Axsome Therapeutics Sees AUVELITY Prescription Surge After Alzheimer’s Agitation Launch

Axsome Therapeutics (NASDAQ:AXSM) executives said growth in new prescriptions for AUVELITY and an expanded sales team are positioning the company for further growth following the drug’s launch for Alzheimer’s disease agitation.

Speaking at the UBS Biopharma Conference in London, Chief Financial Officer Nick Pizzie said Axsome reported $260 million in total net sales for the third quarter, representing an annualized run rate of more than $1 billion for the first time. AUVELITY contributed $208 million, up 53% year over year.

Chief Operating Officer Mark Jacobson said early prescriber feedback on AUVELITY for Alzheimer’s disease agitation has been positive and consistent with the drug’s label. The treatment is also used for major depressive disorder, or MDD.

Prescription Growth and Sales Expansion

Pizzie described new-to-brand prescriptions, or NBRxs, as a leading indicator of future growth. He said AUVELITY’s NBRxs had risen more than 200% year over year, increasing from an average of 2,400 per week in the first quarter to 3,600 and reaching 3,800 in October.

For patients age 65 and older, a proxy the company uses for Alzheimer’s disease agitation, monthly new-to-brand prescriptions rose from an average of 1,000 before the April 2026 approval to 3,600, Pizzie said.

Axsome has expanded its field force from about 270 representatives at the start of the year to more than 650, including its long-term care team. Jacobson said the company typically expects an initial impact from a sales force expansion within one to two quarters and is beginning to see that effect.

Jacobson also said the company is seeing prescriptions follow the distribution of AUVELITY samples, although it cannot track how individual patients use the samples. Pizzie said Axsome expects new-to-brand prescriptions to translate into growth in total prescriptions.

Age Data Offers an Imperfect Sales Proxy

Axsome cannot cleanly separate AUVELITY sales by indication, Pizzie said. Patients age 65 and older accounted for approximately 13.5% of AUVELITY prescriptions in the third quarter, compared with roughly 9.5% to 10% in the first and second quarters.

Applying the third-quarter percentage to AUVELITY’s revenue would suggest approximately $30 million, Pizzie said, while cautioning that the older age group also includes patients treated for depression. He added that the company’s under-65 business, used as a proxy for MDD, grew 33% year over year in the third quarter, compared with 31% in the second quarter.

Asked about competition from CAPLYTA in depression, Jacobson said Axsome had not seen an impact on AUVELITY. He described the products as distinct, with different patient profiles and use cases.

Pizzie reiterated the company’s view of an approximately $8 billion peak sales opportunity, split roughly evenly between Alzheimer’s disease agitation and MDD. He declined to comment on a question about 2027 consensus estimates, saying Axsome does not provide that form of guidance.

Pipeline Updates

Beyond AUVELITY, Pizzie said SUNOSI generated $48 million in third-quarter revenue, including an $8.5 million milestone payment. SYMBRAVO generated approximately $4 million.

Jacobson said Axsome expects top-line results next year from the ENGAGE study of solriamfetol, marketed as SUNOSI, in binge eating disorder. A positive result would allow the company to proceed with a second study needed to seek an additional indication, he said.

The company also expects results later next year from two solriamfetol trials in attention-deficit/hyperactivity disorder. Other studies involve MDD patients with excessive daytime sleepiness and shift work disorder, Jacobson said.

For AXS-20 in schizophrenia, Jacobson said Axsome is conducting a technology transfer and plans to initiate a Phase 3 trial in the coming year. He said the company sees potential for the drug’s mechanism to differentiate it, including through tolerability, but that further study is needed.

About Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau. Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.